Molecular Formula | C10H8BrN3O |
Molar Mass | 266.09 |
Density | 1.6292 (rough estimate) |
Melting Point | 285-287° (Stevens); mp 246-248° (Brown, Stevens) |
Boling Point | 389.7±52.0 °C(Predicted) |
Water Solubility | 7.8mg/L(37 ºC) |
Solubility | DMSO: ≥5mg/mL (warm DMSO) |
Appearance | powder |
Color | white to beige |
pKa | 3.18; 8.53(at 25℃) |
Storage Condition | room temp |
Refractive Index | 1.6520 (estimate) |
Hazard Symbols | Xn - Harmful |
Risk Codes | R63 - Possible risk of harm to the unborn child R62 - Possible risk of impaired fertility |
WGK Germany | 3 |
RTECS | UW7351300 |
use | brompiridine is an aryl pyrimidine anti-metabolic anti-tumor drug, a bladder cancer chemotherapy drug jointly developed by the United States and Japan. |
biological activity | Bropirimine is a synthetic agonist of toll-like receptor 7 (TLR7). Bropirimine the production of IFN-β mediated by TLR7 inhibits the differentiation of osteoclast precursor cells into osteoclasts. Bropirimine is an orally active immunomodulator with anticancer activity in orthotopic transitional cell carcinoma (CIS) of the bladder and upper urinary tract. |
category | toxic substances |
toxicity classification | poisoning |
acute toxicity | oral-rat LD50:>3200 mg/kg |
flammability hazard characteristics | combustible; combustion produces toxic nitrogen oxides and bromide smoke |
storage and transportation characteristics | warehouse ventilation and low temperature drying |
fire extinguishing agent | dry powder, foam, sand, carbon dioxide, mist water |